Lexiscan (Regadenoson) Dosing in ESRD
Yes, regadenoson (Lexiscan) can be administered at the standard 0.4 mg dose without reduction in patients with end-stage renal disease (ESRD), including those on dialysis.
FDA-Approved Dosing
The FDA drug label explicitly states: "No dose adjustment is needed in patients with renal impairment including patients with end stage renal disease and/or dependent on dialysis" 1. This represents the highest level of prescribing authority and should guide clinical practice.
Pharmacokinetic Rationale
While regadenoson is predominantly renally excreted (57% unchanged in urine), the pharmacokinetic profile supports standard dosing in ESRD 1:
- Maximum plasma concentrations remain similar across all levels of renal function, including severe impairment
- Early plasma concentration-time profiles are not significantly altered when most pharmacologic effects occur (within the first 1-4 minutes)
- The initial half-life (2-4 minutes) and intermediate phase (30 minutes) that coincide with coronary vasodilation are not meaningfully affected by renal dysfunction
- Although elimination half-life and AUC increase with worsening renal function, this occurs in the terminal phase (after pharmacodynamic effects have resolved)
Safety Evidence
Multiple studies confirm the safety profile in ESRD patients 2, 3:
- No serious adverse events, medication-related hospitalizations, or deaths occurred in ESRD patients within 30 days of regadenoson administration 2
- The hemodynamic response and side effect profile are similar between ESRD patients and those with normal renal function 2, 3
- In the largest prospective evaluation (146 ESRD patients), there was no significant difference in the composite incidence of adverse effects compared to controls (74% vs 75%, P=0.82) 3
- Heart rate and blood pressure changes were comparable between groups
Clinical Considerations
Timing with dialysis: While regadenoson is dialyzable in vitro 1, the rapid pharmacodynamic effect (peak within 1-4 minutes) means the drug exerts its clinical effect well before dialysis could remove it. No specific timing relative to dialysis sessions is required.
Monitoring: Standard post-stress monitoring is appropriate. No additional renal function monitoring is needed specifically for regadenoson administration.
Aminophylline availability: Ensure aminophylline (50-250 mg IV) is available for reversal of severe or persistent adverse reactions, though this is rarely needed 1, 4.
Common Pitfall to Avoid
Do not reduce the dose based solely on ESRD status. The 0.4 mg dose is a fixed, weight-independent dose that has been validated across all levels of renal function. Dose reduction would result in inadequate coronary vasodilation and suboptimal myocardial perfusion imaging.